Indaptus Therapeutics, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a INDP research report →
Companyindaptusrx.com
Indaptus Therapeutics, Inc. , a pre-clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical oncology candidate is Decoy20 to single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as hepatitis B virus and human immunodeficiency virus infection, which is in Phase I clinical trial.
- CEO
- Junyi Dai
- IPO
- 2015
- Employees
- 7
- HQ
- New York City, NY, US
Price Chart
Valuation
- Market Cap
- $2.15M
- P/E
- -0.71
- P/S
- 0.00
- P/B
- 10.80
- EV/EBITDA
- -0.04
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -1028.81%
- ROIC
- -1396.04%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-20,848,916 · -38.79%
- EPS
- $-21.58 · -1240.37%
- Op Income
- $-19,833,513
- FCF YoY
- -20.29%
Performance & Tape
- 52W High
- $19.91
- 52W Low
- $1.20
- 50D MA
- $2.15
- 200D MA
- $3.02
- Beta
- 1.37
- Avg Volume
- 56.41K
Get TickerSpark's AI analysis on INDP
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Apr 8, 26 | Lu Qinglai | other | 0 |
| Mar 23, 26 | Yao Yun | other | 0 |
| Mar 23, 26 | SINO LION VENTURES Ltd | other | 0 |
| Mar 23, 26 | Dai Junyi | other | 0 |
| Mar 23, 26 | Lazar David E. | sell | 196,800 |
| Mar 23, 26 | Lazar David E. | sell | 700,000 |
| Feb 26, 26 | Jabbour Jerome D | other | 25,000 |
| Feb 26, 26 | Jabbour Jerome D | other | 0 |
| Feb 26, 26 | McMurdo Matthew Charles | other | 0 |
| Feb 11, 26 | Meckler Jeffrey A | other | 12,136 |
Our INDP Coverage
We haven't published any research on INDP yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate INDP Report →